Literature Search Results
Table 1 summarizes the key demographic characteristics of all trials
previously done between the period of 1988 to 2020, including patients
with diabetes. Five trials were eligible out of 13 trials which included
only patients with diabetes for the analysis to rule out the efficacy of
Aspirin for cardiovascular events. Table 2 summarizes the trials
investigating the effect of Aspirin in the primary prevention of
cardiovascular events and its risk of bleeding outcomes in individuals
only with diabetes.
The present Meta-analysis comprised 23,570 diabetic patients; 11,738
allocated to Aspirin and 11,832 allocated to the control or placebo
group.